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ObesityInclusion of Tat-activating regulatory DNA-binding protein-43 (TDP-43) due to hyperphosphoryla-
tion or hyperubiquitination is a cause of neurodegenerative disease. Cellular TDP-43 expression is
tightly controlled through a negative feedback loop involving its mRNA. Recently, we reported that
the TDP-43-mediated sub-nuclear body is an essential site of interleukin-6 (IL-6) pre-mRNA process-
ing. Here we show that mice fed on a high-fat diet exhibit increased TDP-43 expression in the liver
and adipose tissue with a prominent increase in IL-6. TDP-43 depletion in vivo reduces IL-6 produc-
tion in the liver. Overexpression or depletion of TDP-43 in pre-adipose and adipose cells causes
reciprocal alteration of IL-6 expression and RNA processing. Our ﬁndings provide evidence for a link
between homeostasis of TDP-43 expression and the risk of developing obesity.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tat-activating regulatory DNA-binding protein-43 (TDP-43) is
structurally related to the family of heterogeneous nuclear ribonu-
cleoproteins and is involved in RNA processing [1]. This protein
was originally identiﬁed as a transcription factor that binds to
the human immunodeﬁciency virus transactivation response
region to repress transactivation response-mediated transcription
[2]. Structurally, TDP-43 contains two classical RNA recognition
motif (RRM) domains ﬂanked on either side by N-terminal and
glycine-rich C-terminal domains. The RRM1 domain is necessary
for nucleic-acid binding, but the RRM2 domain does not play a sig-
niﬁcant role in RNA binding. The C-terminal glycine-rich domain is
important for protein–protein interactions [3,4]. TDP-43 is a major
component of the cytoplasmic inclusions that characterize the cen-
tral nervous system pathology involved in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis [5,6]. In normal
cells, TDP-43 is localized mainly in the nucleus, while in affected
cells, ubiquitinated TDP-43 aggregates are mislocalized in thecytoplasm due to mutations within the TDP-43 gene [6].
Aberrantly truncated and phosphorylated TDP-43 is also present
in the intracellular ubiquitinated cytoplasmic inclusions [6,7].
Interleukin-6 (IL-6) is a soluble mediator with pleiotropic
effects on inﬂammation, immune response, and hematopoiesis;
therefore, dysregulation of IL-6 expression results in pathological
effects related to chronic inﬂammation and autoimmunity. In par-
ticular, obese patients exhibit sustained liver inﬂammation and
increased plasma IL-6 levels [8]; thus, IL-6 is a possible molecular
marker for obesity-induced inﬂammation. We previously
reported that TDP-43-containing sub-nuclear bodies are speciﬁc
cytokine-splicing compartments important for efﬁcient RNA pro-
duction during activation and modulation of the immune response
[9]. In addition, knockdown of TDP-43 disrupts the regulation of
IL-6 expression and RNA processing. Although TDP-43 controls
its own homeostasis by downregulating transcript levels [10], a
possible correlation between aberrant TDP-43 overexpression
and IL-6 hyperproduction in obesity may exist.
Here, we demonstrate that TDP-43 expression is highly elevated
in the liver and adipose tissue in concert with increased IL-6 levels
in high-fat diet-fed mice. Speciﬁcally, overexpression of TDP-43
signiﬁcantly enhances IL-6 levels in pre-adipocytes, adipocytes,
and macrophages. The effect of TDP-43 overexpression on IL-6 pro-
duction in these cells, along with its positive correlation with obe-
sity, is concordant with TDP-43’s role as a critical regulator of IL-6
RNA processing. Indeed, depletion of TDP-43 in vivo leads to a
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liver of mice. Taken together, these results suggest that
TDP-43-dependent regulation of IL-6 expression underlies the
pathological link between TDP-43 and obesity.
2. Materials and methods
2.1. DNA constructs
Mouse TDP-43 construct was fused at the N-terminus to HA and
cloned into the retroviral pLHCX (Hygro) vector (Clontech,
Mountain View, CA). The shRNA sequence against TDP-43 was
annealed and subcloned into the pSUPER retroviral vector
(Oligoengine, Seattle, WA) using the following primers: 50-GATCC
GCGATGAACCCATTGAAATACTCGAGTATTTCAATGGGTTCATCGTTTT
TTGGAAA-30 and 50-AGCTTTTCCAAAAAACGATGAACCCATTGAAATA
CTCGAGTATTTCAATGGGTTCATCGCG-30. The shRNA sequence
against GFP, which was used as a negative control, was subcloned
using the following primers: 50-GATCCGCAAGCTGACCCTGAAGTTC
CTCGAGGAACTTCAGGGTCAGCTTGCTTTTTTGGAAA-30 and 50-AGCT
TTTCCAAAAAAGCAAGCTGACCCTGAAGTTCCTCGAGGAACTTCAGGG
TCAGCTTGCGG-30. All constructs were veriﬁed by sequencing.
2.2. Antibodies
Antibodies against TDP-43 (#A303-223A), b-actin (#A5316),
tubulin (#G094) and GAPDH (#sc-32233) were obtained from
Bethyl Laboratories (Montgomery, TX), Sigma (St. Louis, MO),
ABM Inc. (Richmond, Canada) and Santa Cruz Biotechnology
(Santa Cruz, CA) respectively.
2.3. Adipocyte differentiation
3T3-L1 cells were cultured in DMEM with bovine calf serum
(Life Technologies, Carlsbad, CA) and 1% antibiotics (HyClone,
Logan, UT). 3T3-L1 cells were induced to differentiate into adipo-
cytes. Brieﬂy, after 2 days of conﬂuence (day 0), cells were stimu-
lated with DMEM containing 10% fetal bovine serum (FBS) and
MDI (0.5 mM isobutylmethylxanthine, 1 lM dexamethasone, and
10 lg/ml insulin; Sigma). After 2 days, the medium was changed
to DMEM containing 10% FBS and 10 lg/ml insulin. The medium
was then changed to DMEM containing 10% FBS and changed every
2 days. Differentiation was achieved by day 10–12.
2.4. Animals and diets
Five-week-old male C57BL/6N mice were obtained from Orient
Bio (Gyeonggi-do, South Korea). All animals were housed in speciﬁc
pathogen-free conditions at 21 ± 2.0 C temperature with 50 ± 5%Table 1
PCR primer sequences and sizes of pre-mRNA or mRNA.
Gene Size of pre-mRNA Size o
IL-6
(RT-PCR)
332 167
IL-6
(qRT-PCR)
1338 112
TNF-a
(RT-PCR)
634 340
TDP-43
(RT-PCR/qRT-PCR)
3417 405
GAPDH
(RT-PCR)
594 376
GAPDH
(qRT-PCR)
1931 97relative humidity and a 12 h-light/12 h-dark cycle. Before the diet
intervention was started, all animals were fed standard chow. At
the beginning of the study, mice were divided into 2 groups: (1)
control group fed the normal diet (ND, n = 8) and (2) a group fed
the high-fat diet (HFD, n = 8). Mice were provided food and water
ad libitum. The body weight and food intake were monitored
throughout the study. At 12 weeks after the initiation of the study,
8 animals from each group were sacriﬁced. Mouse serum was col-
lected for ELISA assay. Tissues were snap-frozen immediately in liq-
uid nitrogen and stored at 80 C until further processing.
2.5. Retroviral transduction
HEK 293T cells were transfected with plasmids encoding VSV-G
and Gag-Pol, as well as either HA-TDP-43, shRNA for TDP-43, or
negative control shRNA for GFP. Approximately 36–48 h
post-transfection, media containing viral particles were collected,
ﬁltered through a 0.45-lm membrane, and incubated with RAW
macrophages or pre-adipocytes for 24 h. Cells were selected with
hygromycin or puromycin.
2.6. ELISA
Mouse serum or tissue culture supernatant was collected, and
IL-6 levels were analyzed by ELISA according to the manufacturer’s
recommendations (BD Biosciences, San Jose, CA).
2.7. Immunoﬂuorescence assay
For immunoﬂuorescent staining, cells were ﬁxed in 3.7%
formaldehyde and permeabilized with 0.2% Triton X-100 prior to
incubation with the appropriate primary antibody. Bound antibody
was visualized with an Alexa Fluor 488-conjugated secondary anti-
body (Life Technologies). DAPI (40,6-diamidino-2-phenylindole;
Sigma) was used as a nuclear counterstain.
2.8. Real-time PCR and RT-PCR assays
Total cellular RNA was prepared using an RNA prep kit (GeneAll,
Seoul, South Korea). Then, 500 ng total RNA was reverse tran-
scribed for 1 h with random hexamers at 42 C using Moloney
Murine Leukemia Virus (M-MLV) reverse transcriptase
(Enzynomics, Daejeon, South Korea). PCR was performed using
the following conditions: 30 cycles of 15 s at 94 C, 15 s at the
experimentally determined optimal annealing temperature (56–
58 C), and 60 s per 1 kb at 72 C (15–40 s). PCR products were
visualized on ethidium bromide-stained gels. GAPDH was used
for normalization. Real-time PCR was performed using TOPreal
qPCR premix (SYBR Green, Enzymonics) and Applied Biosystems
7300 Real-Time PCR System (Life Technologies). Results weref mRNA Forward Primer (Target region)
Reverse Primer (Target region)
50-ACCGCTATGAAGTTCCTCTCTGCA-30 (Exon 1)
50-AAGCCTCCGACTTGTGAAGTGGT-30 (Exon 2)
50-GTCCTTCAGAGAGATACAGAAACT-30 (Exon 4)
50-AGCTTATCTGTTAGGAGAGCATTG-30 (Exon 5)
50-ACAAGCCTGTAGCCCACGTC-30 (Exon 3)
50-AAGACTCCTCCCAGGTATATGG-30 (Exon 4)
50-ATGTCTGAATATATTCGGGTAACAGAAG-30 (Exon1)
50-GACCTGAACCATAAGAACCTCTCC-30 (Exon2)
50-CCTGGCCAAGGTCATCCATG-30 (Exon 3)
50-GCAGGAGACAACCTGGTCCT-30 (Exon 5)
50-CCTGGCCAAGGTCATCCATG-30 (Exon 1)
50-GCAGGAGACAACCTGGTCCT-30 (Exon 2)
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quantiﬁed by the change-in-threshold method (DDCT). All primer
sequences are listed in Table 1.
2.9. In vivo RNAi experiment
TDP-43 expression was knocked down in live mice with
TDP-43-speciﬁc siRNA using Invivofectamine (Invitrogen). The
siRNA-Invivofectamine complex was prepared according to the
manufacturer’s protocol. Brieﬂy, siRNA (3 mg/ml) was mixed with
complexation buffer and Invivofectamine, incubated for 30 min
at 50 C, and dialyzed at room temperature for 2 h in
phosphate-buffered saline (PBS; pH 7.4). Dialyzed
siRNA-Invivofectamine complex (7 mg/kg) was injected via tail
veins of female C57BL/6 (5 or 6 weeks old). Two days later, mice
were treated intraperitoneally with LPS (5 mg/kg). After 9 h treat-
ment, mice were euthanized and liver tissues were collected for
qRT-PCR or RT-PCR.
2.10. Immunoblot analysis
Cell lysates were separated by SDS–PAGE, transferred onto
nitrocellulose membranes, blocked with 5% skim milk in PBS con-
taining 0.1% Tween-20 (Sigma) for 2 h, and then probed with the
appropriate antibody for 4 h at RT. Membranes were washed three
times with PBS containing 0.1% Tween-20 and incubated with
horseradish peroxidase-conjugated streptavidin for 1 h. Bands
were visualized using an ECL detection reagent (AbClon, Seoul,
South Korea).
2.11. Ethics statement
All animal experiments were performed in accordance with the
Korean Food and Drug Administration (KFDA) guidelines. Protocols
were reviewed and approved by the Institutional Animal Care and
Use Committee (IACUC) of the Yonsei Laboratory Animal Research
Center (YLARC) at Yonsei University (Permit Number: 2007-0001).
2.12. Statistical analysis
All experiments were repeated at least three times with consis-
tent results. Data are presented as mean and S.D. or S.E.M. (as
noted in ﬁgure legends). Statistical differences between two means
were evaluated with a two-tailed unpaired Student’s t-test.
Differences with P-values less than 0.05 were considered signiﬁ-
cant. No samples were excluded from the analysis. The data had
a normal distribution, and the variance was similar between the
groups being compared. No statistical method was used to prede-
termine sample sizes. Sample size was based on previous experi-
ence with experimental variability. The experiments were not
randomized. The investigators were not blinded to allocation dur-
ing experiments or outcome assessment.
3. Results
3.1. High expression levels of TDP-43 in HFD-induced obesity
As previously noted, the TDP-43-containing sub-nuclear body is
involved in IL-6 RNA processing [9]. Since TDP-43 levels are under
tight control via a negative feedback loop at the mRNA level [10],
TDP-43 overexpression may affect IL-6 overproduction, which is
strongly relatedwith inﬂammatory diseasephenotypes such as obe-
sity. To investigate the relationship between aberrant TDP-43 over-
expression and obesity, we ﬁrst analyzed the body weight and IL-6
levels in C57BL/6N mice fed a HFD compared to those animals fed
a ND. The body weights of HFD mice continued to increase overthe course of experimental feeding, and the difference in weight
between the two groups was approximately 45% at 12 weeks
(Fig. 1A, left). TheHFDmice also exhibited signiﬁcantly higher levels
of IL-6 than ND mice (Fig. 1A, right). To determine if IL-6 levels cor-
relate with TDP-43 expression during obesity, we assessed TDP-43
expression in the liver and adipose tissue (epididymal and
subcutaneous fat) of HFD mice. Interestingly, TDP-43 mRNA and
protein levels were signiﬁcantly increased in the liver and adipose
tissue of HFD mice compared to ND mice (Fig. 1B and C).
These results indicate that increased TDP-43 expression levels are
positively linked to elevated IL-6 expression and obesity.
3.2. TDP-43 expression directly impacts IL-6 production in pre-
adipocytes, adipocytes, and macrophages
Adipose tissue is a main source of IL-6 during obesity [11,12], so
to further examine the role of TDP-43 in obesity, we generated
pre-adipose and adipose cell lines that stably overexpress
HA-TDP-43 and then evaluated their IL-6 production.
Interestingly, we found that overexpression of TDP-43 signiﬁcantly
increased IL-6 levels in culture supernatants (Fig. 2A). To conﬁrm
this association, we analyzed the effect of TDP-43 depletion on
IL-6 levels in both cell lines. In contrast to results regarding
TDP-43 overexpression, TDP-43-depleted pre-adipose and adipose
cells showed considerably reduced IL-6 production (Fig. 2B).
Examination of TDP-43’s effect on IL-6 RNA processing revealed
that IL-6 mRNA stability increased in TDP-43-overexpressed
pre-adipocytes (Fig. 2C) and that levels of IL-6 mRNA were reduced
in TDP-43-depleted pre-adipocytes and adipocytes (Fig. 2D, arrow-
heads). However, levels of TNF-a mRNA were unaffected (Fig. 2D),
as TDP-43 binds RNAs in a sequence-speciﬁc manner [9].
Moreover, knockdown of TDP-43 induced the accumulation of
unspliced IL-6 pre-mRNA, indicating signiﬁcant impairment of
IL-6 RNA processing (Fig. 2D, arrows). Because TDP-43-mediated
sub-nuclear foci formation is important for IL-6 production [9],
we speciﬁcally examined TDP-43-enriched foci in pre-adipocytes.
Notably, TDP-43 foci were clearly observed in pre-adipose cells
in the presence or absence of lipopolysaccharide (LPS) stimulation
(Fig. 2E), demonstrating that TDP-43 expression is strongly associ-
ated with IL-6 production in pre-adipose and adipose cells.
Because adipose tissue also contains immune cells, including
macrophages, we also explored if increased TDP-43 expression
affected IL-6 production in macrophages. When TDP-43 was over-
expressed in RAW macrophages, IL-6 levels were signiﬁcantly
increased in culture supernatants following LPS stimulation com-
pared to supernatants from non-TDP-43-overexpressing cells
(Supplementary Fig. 1A). To analyze IL-6 mRNA levels in
TDP-43-overexpressing macrophages, we performed qRT-PCR and
observed that elevated TDP-43 expression led to increased IL-6
mRNA levels (Supplementary Fig. 1B). Taken together, these data
suggest that IL-6 expression levels are strongly dependent on the
expression of TDP-43 in various cell types within adipose tissue.
3.3. Effect of in vivo TDP-43 depletion on liver inﬂammation
Previous reports have shown that obesity is linked to hepatic
inﬂammation and insulin resistance [13,14]. In addition, liver tis-
sue releases large amounts of IL-6, suggesting that the liver and
adipose tissue are major sources of IL-6 production [15,16].
Because we observed a strong correlation between TDP-43 overex-
pression and IL-6 levels in obese mice, we investigated the physi-
ological relevance of TDP-43 expression during liver
inﬂammation. We induced in vivo TDP-43 depletion and subse-
quent liver inﬂammation in the mice by intraperitoneal injection
with LPS (Fig. 3A, left) and observed signiﬁcantly depleted
TDP-43 in the liver (Fig. 3A, right). Notably, TDP-43-depleted mice
Fig. 1. Elevated expression of TDP-43 and IL-6 in obesity. C57BL/6N mice were divided into two groups: control mice fed a normal diet (ND) and experimental mice fed a
high-fat diet (HFD). (A) The body weights of these mice were measured at 12 weeks, and serum IL-6 levels from HFD or ND mice were measured by ELISA (n = 8). *P < 0.01,
**P < 0.05 (Student’s t-test). (B and C) Expression of TDP-43 in HFD or ND mice. TDP-43 mRNA or protein expression in the epididymal (Epi), subcutaneous fat (Subc), and liver
tissues of HFD or ND mice was assessed by RT-PCR (B) or immunoblot (C) analysis (n = 8). *P < 0.005, **P < 0.01 (Student’s t-test). Data are representative of at least three
independent experiments (mean ± S.D. in A–C).
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wild-type mice (Fig. 3B). Furthermore, IL-6 RNA processing was
markedly impaired by in vivo TDP-43 depletion, even after induc-
tion of liver inﬂammation (Fig. 3C). In addition, levels of
C-reactive protein mRNA, primarily induced by IL-6-dependent
liver inﬂammation, were also decreased in the liver of
TDP-43-depleted mice (Supplementary Fig. 2A). Our ﬁndings
related to in vivo TDP-43-depletion are consistent with our
in vitro data from the cell-base analysis. Thus, we conclude that
TDP-43 overexpression promotes liver inﬂammation by accelerat-
ing IL-6 mRNA production.
4. Discussion
In this study, we showed that aberrant TDP-43 overexpression
leads to IL-6 overproduction in obese mice, thereby suggesting that
TDP-43 plays a critical role in homeostasis of IL-6 production.
Although the loss of nuclear TDP-43 function by its mislocalization
in the cytoplasm and by mutations in the TARDBP gene is associ-
ated with neurodegenerative diseases [17], it is not clear whether
altered TDP-43 expression is linked to immunological pathogene-
sis. Considering the self-regulation of TDP-43 levels via a negative
feedback loop [10], this study strongly supports the notion that
control of TDP-43 is important to prevent IL-6-dependent patho-
logical conditions.
Cytokines are used in multiple signaling pathways to elicit their
biological effects, and cytokine signals are rapidly attenuated tomaintain cellular processes and avoid toxic side effects. In particu-
lar, IL-6 is an important mediator involved in the regulation of the
acute-phase response to injury and infection, neuronal regenera-
tion, embryonic development, and fertility [18–21]. Thus, dysregu-
lation of IL-6 signaling leads to the onset andmaintenance of several
pathological diseases. Speciﬁcally, IL-6 levels are signiﬁcantly high
in obese patients [8]. Obesity-associated increases in IL-6 levels
are linked to decreased insulin-induced glucose uptake [22], and
IL-6 decreases insulin sensitivity by suppressing adiponectin
mRNA synthesis and secretion [23]. Therefore, elevated TDP-43
and IL-6 levels in HFDmice implicate that TDP-43 is associatedwith
the obesity-related conditions. Previous reports have shown that
TDP-43 regulates Tbc1d1, a key regulator of glucose homeostasis
and obesity, and that TDP-43 overexpression increases Tbc1d1
mRNA levels in skeletal muscle cells [24,25]. However, overex-
pressed TDP-43 does not affect Tbc1d1 mRNA expression levels in
adipose tissues, [25], nor does in vivo TDP-43 depletion inﬂuence
Tbc1d1 mRNA expression in the liver of mice (Supplementary
Fig. 2B). These results suggest that differential regulation of
TDP-43 in various cell types inﬂuences its role during obesity.
Adipose tissue contains adipocytes, pre-adipocytes, endothelial
cells, ﬁbroblasts, leukocytes, andmacrophages. Adipocytes produce
IL-6 during obesity, and pre-adipocytes from stromal vascular frac-
tions signiﬁcantly contribute to obesity-induced IL-6 expression
[26]. Macrophages are also central mediators of obesity-associated
inﬂammation. Therefore, the effect of TDP-43 on IL-6 levels in these
cells suggests TDP-43’s involvement in obesity-induced pathogenic
Fig. 2. TDP-43-dependent IL-6 expression in pre-adipocytes and adipocytes. (A) Levels of IL-6 in control or HA-TDP-43-overexpressing pre-adipocytes and adipocytes were
analyzed by ELISA. *P < 0.01 (Student’s t-test). Levels of TDP-43 were analyzed by immunoblot using anti-TDP-43 antibodies. (B) ELISA was performed to measure IL-6 levels
from control or TDP-43-depleted pre-adipocytes and adipocytes. *P < 0.01, **P < 0.005 (Student’s t-test). Levels of TDP-43 were conﬁrmed by immunoblot analysis using anti-
TDP-43 antibodies. (C) The effect of TDP-43 overexpression on mRNA stability in pre-adipocytes was assessed by qRT-PCR analysis. RNA was isolated at indicated time points
after actinomycin D (Act D) treatment. *P < 0.01 (Student’s t-test). (D) Effect of TDP-43 knockdown on cytokine RNA processing in pre-adipocytes and adipocytes. Primer pairs
for the exon–exon junction of the indicated cytokines were used. TDP-43 knockdown and quantity of total RNA were conﬁrmed by RT-PCR using the indicated primers
(Table 1). Arrowheads and arrows indicate mRNA and pre-mRNA, respectively. (E) Immunoﬂuorescence assays analyzed pre-adipocytes after treatment with or without LPS.
Cells were stained with anti-TDP-43 antibodies, and DAPI was used as a nuclear counterstain. Scale bars, 5 lm. Data are representative of at least three independent
experiments (mean ± S.D. in A–C).
S. Lee et al. / FEBS Letters 589 (2015) 1825–1831 1829
Fig. 3. Effect of in vivo TDP-43 depletion on liver inﬂammation. (A) Strategy for depletion of TDP-43 in vivo and induction of liver inﬂammation by LPS. C57BL/6N mice were
divided into two different groups: control mice injected with the control-Invivofectamine complex (n = 4) and experimental mice injected with the TDP-43 siRNA-
Invivofectamine complex (n = 4). The efﬁciency of TDP-43 depletion was conﬁrmed by immunoblot analysis using anti-TDP-43 antibodies. (B) qRT-PCR revealed a signiﬁcant
reduction in IL-6 mRNA production. All qRT-PCR data were normalized to the expression of GAPDH mRNA (n = 4). *P < 0.01, **P < 0.005 (Student’s t-test). (C) RT-PCR using
primer pairs for the exon 1–exon 2 junction of IL-6 RNA was performed on control or TDP-43-depleted mice. Conﬁrmation of TDP-43 knockdown and measurement of the
quantity of RNA were conﬁrmed by RT-PCR. Arrowheads and arrows indicate mRNA and pre-mRNA, respectively. Data are representative of at least three independent
experiments (mean ± S.E.M. in B).
1830 S. Lee et al. / FEBS Letters 589 (2015) 1825–1831conditions. In addition, obesity leads to hepatic inﬂammation and
IL-6 over-production [14,27]. Our results show that alteration of
TDP-43 expression obviously affects IL-6 expression in the liver,
suggesting a potential link between TDP-43 and liver inﬂammation
during obesity.
In conclusion, we observed regulation of IL-6 expression via
TDP-43 and TDP-43’s involvement in the pathogenesis of obesity.
Because IL-6 inﬂuences obesity pathogenesis and affects disease
severity, defective regulation of IL-6 via aberrant TDP-43 expres-
sion could serve as a reliable indicator of certain inﬂammatory dis-
eases. Based on our ﬁndings, these diseases could also be
characterized by excessive TDP-43 expression. Although questions
remain regarding TDP-43’s complete role in obesity, our study pro-
vides valuable insight into the molecular pathology of obesity and
may contribute to the development of improved therapies for
treating obesity-related diseases.
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